Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,377 | 393 | 2,955 |
| Samples | 338 | 73 | 260 |
| Peptides | 307 | 51 | 265 |
Function
GRB10 · Growth factor receptor bound protein 10
The product of this gene belongs to a small family of adapter proteins that are known to interact with a number of receptor tyrosine kinases and signaling molecules. This gene encodes a growth factor receptor-binding protein that interacts with insulin receptors and insulin-like growth-factor receptors. Overexpression of some isoforms of the encoded protein inhibits tyrosine kinase activity and results in growth suppression. This gene is imprinted in a highly isoform- and tissue-specific manner, with expression observed from the paternal allele in the brain, and from the maternal allele in the placental trophoblasts. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Oct 2010].
Isoforms & Proteins
13 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000401949 | Q13322 | 394 | 271 |
| ENST00000398812 | Q13322 | 317 | 235 |
| ENST00000357271 | Q13322-2 | 314 | 228 |
| ENST00000644879 | A0A2R8YCL1* | 271 | 214 |
| ENST00000335866 | Q13322-3 | 260 | 204 |
| ENST00000398810 | Q13322-3 | 259 | 203 |
| ENST00000402497 | Q13322-3 | 259 | 203 |
| ENST00000402578 | Q13322-3 | 259 | 203 |
| ENST00000403097 | Q13322-3 | 259 | 203 |
| ENST00000406641 | Q13322-3 | 259 | 203 |
| ENST00000407526 | Q13322-3 | 259 | 203 |
| ENST00000643299 | Q13322-3 | 259 | 203 |
| ENST00000645075 | Q13322-3 | 8 | 8 |
Gene Properties
Recurrent Mutations
All 271 amino-acid changes on canonical ENST00000401949 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRB10 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRB10 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 23/612 4% |
| Hodgkins Lymphoma | 3/16 19% | 1/122 1% |
| Unknown | 0/10 0% | 1/29 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Other Solid Cancers | 1/94 1% | 26/1515 2% |
| Colorectal Carcinoma | 14/143 10% | 41/3239 1% |
| Melanoma | 5/210 2% | 26/1899 1% |
| Cervical Carcinoma | 1/35 3% | 5/422 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 17/1390 1% |
| Gastric Carcinoma | 4/74 5% | 18/1809 1% |
| Other Sarcomas | 2/69 3% | 5/699 1% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Esophageal Carcinoma | 2/23 9% | 5/769 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 6/810 1% |
| Non-Cancerous | 1/104 1% | 6/830 1% |
| Ovarian Carcinoma | 4/109 4% | 2/998 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Biliary Tract Carcinoma | 3/54 6% | 2/950 0% |
| Hepatocellular Carcinoma | 3/46 7% | 8/2210 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 6/1592 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Glioma | 1/52 2% | 8/2127 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 9/2550 0% |
| Breast Carcinoma | 2/144 1% | 9/3264 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
Mutation Distribution
Where GRB10 is mutated · all tissues, split by cell line vs tissue
How many mutations in GRB10 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,377 mutations in GRB10
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|